Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine

NCT04152083 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT04152083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04152083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Completed
Start date
November 7, 2019
Completion date
July 8, 2020
Enrollment
485 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

migraine